Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.
Emory University Hospital, Atlanta, Georgia.
JAMA Cardiol. 2019 Jan 1;4(1):64-70. doi: 10.1001/jamacardio.2018.4320.
IMPORTANCE: In low-flow, low-gradient aortic stenosis (LFLG AS), the severity of left ventricular dysfunction remains a key factor in the evaluation of aortic valve replacement. OBJECTIVE: To evaluate the clinical outcomes and changes in left ventricular ejection fraction (LVEF) after transcatheter aortic valve replacement (TAVR) in patients with LFLG AS and severe left ventricular dysfunction. DESIGN, SETTING, AND PARTICIPANTS: This multicenter registry is a substudy of the True or Pseudo-Severe Aortic Stenosis-TAVI registry that included patients with classic LFLG AS, defined as a mean transvalvular gradient less than 35 mm Hg, an effective orifice area less than 1.0 cm2, and an LVEF of 40% or less. Patients were divided in groups with very low (<30%) LVEF and low (30%-40%) LVEF. Dobutamine stress echocardiography (DSE) was performed before TAVR in a subset with very low LVEF, and presence of contractile reserve was defined as an increase of 20% or more in stroke volume. Clinical outcomes were assessed at 1 and 12 months and yearly thereafter, and echocardiography was performed at 1-year follow-up. Retrospective data were collected from 2007 to 2013 and prospective data from January 2013 to March 2018. Data were analyzed from March to October 2018. EXPOSURES: Transcatheter aortic valve replacement in patients with LFLG AS. MAIN OUTCOMES AND MEASURES: Changes in LVEF over time; periprocedural and late mortality. RESULTS: A total of 293 patients were included, including 128 (43.7%) with very low LVEF and 165 with low LVEF (56.3%). Their mean (SD) age was 80 (7) years, and most (214 [73.0%]) were men. The mean (SD) LVEF in the very low LVEF group was 22% (5%), compared with 37% (7%) in the low LVEF group (P < .001). There were no differences between groups in rates of periprocedural mortality and late mortality (median [interquartile range], 23 [6-38] months). Patients with very low LVEF displayed a greater increase in LVEF at the 1-year follow-up examination (mean absolute increase, 11.9% [95% CI, 8.8%-15.1%]), than the low LVEF group (3.6% [95% CI, 1.1%-6.1%]; P < .001). In 92 patients with very low LVEF who had preprocedural DSE, results showed a lack of contractile reserve in 45 (49%), but this had no effect on clinical outcomes or changes in LVEF over time. CONCLUSIONS AND RELEVANCE: In patients with LFLG AS and severe left ventricular dysfunction, TAVR was associated with similar clinical outcomes as in counterparts with milder left ventricular dysfunction. The TAVR procedure was associated with a significant increase in LVEF, irrespective of contractile reserve. These results support TAVR for LFLG AS, irrespective of the severity of left ventricular dysfunction and DSE results.
重要性:在低流量、低梯度主动脉瓣狭窄(LFLG AS)中,左心室功能障碍的严重程度仍然是评估主动脉瓣置换的关键因素。 目的:评估 LFLG AS 伴严重左心室功能障碍患者经导管主动脉瓣置换(TAVR)后的临床结局和左心室射血分数(LVEF)变化。 设计、地点和参与者:这项多中心登记研究是真实或假性严重主动脉瓣狭窄-TAVI 登记研究的子研究,纳入了具有典型 LFLG AS 的患者,定义为平均跨瓣梯度<35mmHg,有效瓣口面积<1.0cm2,LVEF<40%。根据非常低(<30%)和低(30%-40%)LVEF 将患者分为两组。非常低 LVEF 患者行多巴酚丁胺负荷超声心动图(DSE)检查,收缩储备的存在定义为每搏量增加 20%或更多。在 1 个月和 12 个月时评估临床结局,此后每年评估一次,在 1 年随访时行超声心动图检查。回顾性数据收集于 2007 年至 2013 年,前瞻性数据收集于 2013 年 1 月至 2018 年 3 月。数据于 2018 年 3 月至 10 月进行分析。 暴露:LFLG AS 患者行 TAVR。 主要结局和测量指标:LVEF 的时间变化;围手术期和晚期死亡率。 结果:共纳入 293 例患者,其中 128 例(43.7%)为非常低 LVEF,165 例为低 LVEF(56.3%)。他们的平均(SD)年龄为 80(7)岁,大多数(214 [73.0%])为男性。非常低 LVEF 组的平均(SD)LVEF 为 22%(5%),而低 LVEF 组为 37%(7%)(P<0.001)。两组间围手术期死亡率和晚期死亡率无差异(中位数[四分位距],23 [6-38] 个月)。非常低 LVEF 组患者在 1 年随访检查时 LVEF 升高更明显(平均绝对升高,11.9%[95%CI,8.8%-15.1%]),高于低 LVEF 组(3.6%[95%CI,1.1%-6.1%];P<0.001)。在 92 例行多巴酚丁胺负荷超声心动图检查的非常低 LVEF 患者中,结果显示 45 例(49%)缺乏收缩储备,但这对临床结局或 LVEF 随时间的变化没有影响。 结论和相关性:在 LFLG AS 伴严重左心室功能障碍的患者中,TAVR 的临床结局与左心室功能障碍较轻的患者相似。TAVR 与 LVEF 的显著升高相关,而与收缩储备无关。这些结果支持 TAVR 治疗 LFLG AS,无论左心室功能障碍的严重程度和 DSE 结果如何。
JACC Cardiovasc Interv. 2020-2-12
Catheter Cardiovasc Interv. 2018-3-1
J Am Coll Cardiol. 2013-6-12
J Thorac Cardiovasc Surg. 2025-5-4
EuroIntervention. 2024-11-18
EuroIntervention. 2024-11-18
Int J Cardiol Cardiovasc Risk Prev. 2024-9-2
Rev Cardiovasc Med. 2022-6-24
J Am Coll Cardiol. 2016-5-24